Success Metrics

Clinical Success Rate

96.7%

Based on 29 completed trials

Completion Rate

97%(29/30)

Active Trials

1(3%)

Results Posted

34%(10 trials)

Terminated

1(3%)

Phase Distribution

Ph phase_1

11%

Ph not_applicable

11%

Ph phase_3

14%

Ph phase_2

28%

Ph phase_4

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution35 total trials

Phase 1Safety & dosage

4(11.4%)

Phase 2Efficacy & side effects

10(28.6%)

Phase 3Large-scale testing

5(14.3%)

Phase 4Post-market surveillance

12(34.3%)

N/ANon-phased studies

4(11.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.5%

29 of 31 finished

Non-Completion Rate

6.5%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(29)

Terminated(2)

Other(4)

Detailed Status

Completed29

unknown4

Withdrawn1

Terminated1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

96.7%

Most Advanced

Phase 4

Trials by Phase

Phase 14 (11.4%)

Phase 210 (28.6%)

Phase 35 (14.3%)

Phase 412 (34.3%)

N/A4 (11.4%)

Trials by Status

completed2981%

withdrawn13%

terminated13%

recruiting13%

unknown411%

Recent Activity

1 active trials

Showing 5 of 36

completedphase_2

Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease

NCT02601586

recruitingphase_4

Clinical Trials (36)

Showing 20 of 36 trialsScroll for more

NCT02601586Phase 2

Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease

Completed

NCT06234995Phase 4

Cortical Electrophysiology of Response Inhibition in Parkinson's Disease

Recruiting

NCT07444892Phase 2

Levodopa for Diabetic Retinopathy

Completed

NCT06275633Not Applicable

Behavioural Profiling of Disease-related Cognitive and Motor Impairment in PD

Completed

NCT03000569Phase 2

A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

Completed

NCT06115538Phase 4

Comparison of Dopamin Level in Idiopathic Parkinson's Patients

Unknown

NCT05901350Not Applicable

The Correlation of Reduction of Levodopa and Non-motor Symptoms of Parkinson's Disease After Deep Brain Stimulation

Completed

NCT02744391Phase 4

A Study of L-DOPA for Depression and Slowing in Older Adults

Completed

NCT03205956Phase 1

Measuring Parkinson's Disease Progression

Completed

NCT03055936Phase 1

Dose-finding Pharmacokinetic Study in Healthy Males

Completed

NCT02769793Phase 4

Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON

Completed

NCT01281475Phase 2

A Trial of Levodopa in Angelman Syndrome

Completed

NCT02560389Phase 4

Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)

Completed

NCT03235037Not Applicable

Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome

Completed

NCT00845000Phase 1

Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)

Completed

NCT01176435Phase 2

Trial of L-DOPA as a Treatment to Improve Vision in Albinism

Completed

NCT00713583Phase 2

Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence

Completed

NCT02641054Phase 2

Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease

Completed

NCT01545856

Cardiovascular Events in Parkinson's Disease Patients

Completed

NCT03119636Phase 1

Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease

Unknown

Drug Details

Intervention Type: DRUG
Total Trials: 36